News

PipelineReview.com21m
Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis
SANDWICH, UK I April 26, 2025 I Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is ...
PipelineReview.com23m
GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
PASADENA, CA, USA I April 26, 2025 I GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that ...
PipelineReview.com28m
AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest ...
PipelineReview.com31m
Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors
CHENGDU, China I April 25, 2025 I Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted ...
PipelineReview.com35m
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiplesolid tumors -- ...
PipelineReview.com46m
CDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025
Data demonstrate potential superiority of antibody-based T cell engager CDR404 over TCR-based approaches, consistent with emerging Phase 1 trial signals of ...
PipelineReview.com48m
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
BOSTON, MA, USA I April 25, 2025 I Nimbus Therapeutics, LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful ...
PipelineReview.com53m
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
PRINCETON, NJ, USA I April 26, 2025 I UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions ...
PipelineReview.com54m
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK, NY, USA I April 26, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational ...
PipelineReview.com57m
Iksuda to Present Growing ADC Pipeline at AACR
NEWCASTLE, UK I April 25, 2025 I Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three posters ...